Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
Jul. 01 | New semester, new state of mind | ![]() |
Jun. 26 | Redburn Atlantic Initiates Arkema at Buy | MT |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.67 for the current year.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.86 for the current period. Therefore, the company is undervalued.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 6.86B | - | ||
+3.74% | 104B | A- | ||
-10.18% | 59.99B | A- | ||
+80.95% | 50.92B | B | ||
+8.46% | 36.09B | B | ||
-0.02% | 30.95B | A- | ||
+4.78% | 18.85B | B- | ||
+18.14% | 17.61B | C+ | ||
+9.26% | 13.97B | B- | ||
+78.32% | 13B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AKE Stock
- 0IB0 Stock
- Ratings Arkema